Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136144858> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W3136144858 abstract "Background: Among patients with advanced stage melanoma receiving pembrolizumab, the presence of liver metastasis is an indicator suggestive of poor therapeutic response. A modified treatment strategy by combining transarterial infusion of pembrolizumab with cryoablation was proposed and its efficacy was assessed among this group of patients. Methods: This study retrospectively reviewed the records of 15 melanoma patients with multiple hepatic metastases who received a planned therapy of combined cryoablation with transarterial infusion of pembrolizumab (CATAP) in Sun Yat-sen University Cancer Center from Sep 1st 2018 to May 30th 2019. From 24th July, 2019 onward, the response rates and safety profile of this combination treatment were assessed prospectively with patient follow-up visits. Findings: The overall response rates (ORRs) of CATAP for the entire cohort, patients with primary cutaneous melanoma, with primary uveal melanoma, and patients who failed first-line intravenous pembrolizumab were 20.0%, 22.2%, 16.7%, and 16.7% respectively. The median time to response was 4.5 months and the median progress free survival (PFS) time in the cohort was 2.73 months. The estimated 6- and 12-month PFS rates were 31.0% and 18.6%, respectively, and the estimated 6- and 12-month overall survival (OS) rates were 73.9% and 49.3%, respectively. A significant increase of CD3-CD16+CD56+ cells (P = 0.0124) and a marginally significant decrease of CD4+CD25+ cells (P = 0.0546) were observed three weeks after the first cycle of CATAP therapy. No Grade 3-4 adverse events were observed. Interpretation: This study demonstrated a proof of concept that cryoablation can be safely combined with transarterial PD-1 blockade therapy and achieved synergistic anti-tumor immune response. Trial Registration: The Chinese Trial Register (ChiCTR) identifier was: ChiCTR1900024899. Funding Statement: This work was supported by grants from National Natural Science Foundation of China (No.81801804).Declaration of Interests: The authors indicate no financial relationships.Ethics Approval Statement: The Hospital Ethics Committee of SYSUCC approved this study (B2019-073-01), and patients with prospective follow up signed written informed consent." @default.
- W3136144858 created "2021-03-29" @default.
- W3136144858 creator A5008020180 @default.
- W3136144858 creator A5017150556 @default.
- W3136144858 creator A5019384502 @default.
- W3136144858 creator A5020473726 @default.
- W3136144858 creator A5030976623 @default.
- W3136144858 creator A5035157812 @default.
- W3136144858 creator A5035701638 @default.
- W3136144858 creator A5040027560 @default.
- W3136144858 creator A5055589628 @default.
- W3136144858 creator A5058792328 @default.
- W3136144858 creator A5060542797 @default.
- W3136144858 creator A5072479355 @default.
- W3136144858 creator A5072978027 @default.
- W3136144858 creator A5073390793 @default.
- W3136144858 creator A5075736599 @default.
- W3136144858 date "2019-01-01" @default.
- W3136144858 modified "2023-10-17" @default.
- W3136144858 title "Anti-Tumor Immune Response by Combining Cryoablation and Transarterial Infusion of Pembrolizumab (CATAP) for Liver Metastases of Melanoma" @default.
- W3136144858 doi "https://doi.org/10.2139/ssrn.3457421" @default.
- W3136144858 hasPublicationYear "2019" @default.
- W3136144858 type Work @default.
- W3136144858 sameAs 3136144858 @default.
- W3136144858 citedByCount "0" @default.
- W3136144858 crossrefType "journal-article" @default.
- W3136144858 hasAuthorship W3136144858A5008020180 @default.
- W3136144858 hasAuthorship W3136144858A5017150556 @default.
- W3136144858 hasAuthorship W3136144858A5019384502 @default.
- W3136144858 hasAuthorship W3136144858A5020473726 @default.
- W3136144858 hasAuthorship W3136144858A5030976623 @default.
- W3136144858 hasAuthorship W3136144858A5035157812 @default.
- W3136144858 hasAuthorship W3136144858A5035701638 @default.
- W3136144858 hasAuthorship W3136144858A5040027560 @default.
- W3136144858 hasAuthorship W3136144858A5055589628 @default.
- W3136144858 hasAuthorship W3136144858A5058792328 @default.
- W3136144858 hasAuthorship W3136144858A5060542797 @default.
- W3136144858 hasAuthorship W3136144858A5072479355 @default.
- W3136144858 hasAuthorship W3136144858A5072978027 @default.
- W3136144858 hasAuthorship W3136144858A5073390793 @default.
- W3136144858 hasAuthorship W3136144858A5075736599 @default.
- W3136144858 hasConcept C121608353 @default.
- W3136144858 hasConcept C126322002 @default.
- W3136144858 hasConcept C141071460 @default.
- W3136144858 hasConcept C143998085 @default.
- W3136144858 hasConcept C197934379 @default.
- W3136144858 hasConcept C2777628079 @default.
- W3136144858 hasConcept C2777658100 @default.
- W3136144858 hasConcept C2777701055 @default.
- W3136144858 hasConcept C2778601017 @default.
- W3136144858 hasConcept C2778902805 @default.
- W3136144858 hasConcept C2780057760 @default.
- W3136144858 hasConcept C502942594 @default.
- W3136144858 hasConcept C526805850 @default.
- W3136144858 hasConcept C71924100 @default.
- W3136144858 hasConcept C72563966 @default.
- W3136144858 hasConcept C90924648 @default.
- W3136144858 hasConceptScore W3136144858C121608353 @default.
- W3136144858 hasConceptScore W3136144858C126322002 @default.
- W3136144858 hasConceptScore W3136144858C141071460 @default.
- W3136144858 hasConceptScore W3136144858C143998085 @default.
- W3136144858 hasConceptScore W3136144858C197934379 @default.
- W3136144858 hasConceptScore W3136144858C2777628079 @default.
- W3136144858 hasConceptScore W3136144858C2777658100 @default.
- W3136144858 hasConceptScore W3136144858C2777701055 @default.
- W3136144858 hasConceptScore W3136144858C2778601017 @default.
- W3136144858 hasConceptScore W3136144858C2778902805 @default.
- W3136144858 hasConceptScore W3136144858C2780057760 @default.
- W3136144858 hasConceptScore W3136144858C502942594 @default.
- W3136144858 hasConceptScore W3136144858C526805850 @default.
- W3136144858 hasConceptScore W3136144858C71924100 @default.
- W3136144858 hasConceptScore W3136144858C72563966 @default.
- W3136144858 hasConceptScore W3136144858C90924648 @default.
- W3136144858 hasLocation W31361448581 @default.
- W3136144858 hasOpenAccess W3136144858 @default.
- W3136144858 hasPrimaryLocation W31361448581 @default.
- W3136144858 hasRelatedWork W2344038060 @default.
- W3136144858 hasRelatedWork W2487649631 @default.
- W3136144858 hasRelatedWork W2572266985 @default.
- W3136144858 hasRelatedWork W2607598329 @default.
- W3136144858 hasRelatedWork W2888523609 @default.
- W3136144858 hasRelatedWork W2990357315 @default.
- W3136144858 hasRelatedWork W3136144858 @default.
- W3136144858 hasRelatedWork W4221136450 @default.
- W3136144858 hasRelatedWork W4281695136 @default.
- W3136144858 hasRelatedWork W4281711210 @default.
- W3136144858 isParatext "false" @default.
- W3136144858 isRetracted "false" @default.
- W3136144858 magId "3136144858" @default.
- W3136144858 workType "article" @default.